The Crystal Structure of JNK2 Reveals Conformational Flexibility in the MAP Kinase Insert and Indicates Its Involvement in the Regulation of Catalytic Activity-Reference-Cited by-同舟云学术

The Crystal Structure of JNK2 Reveals Conformational Flexibility in the MAP Kinase Insert and Indicates Its Involvement in the Regulation of Catalytic Activity

Published:2008-11 Issue:4 Volume:383 Page:885-893
ISSN:0022-2836
Container-title:Journal of Molecular Biology
language:en
Short-container-title:Journal of Molecular Biology

Author:

Shaw David,Wang Sandra M.,Villaseñor Armando G.,Tsing Stan,Walter David,Browner Michelle F.,Barnett Jim,Kuglstatter Andreas

Publisher

Elsevier BV

Subject

Molecular Biology,Structural Biology

Reference41 articles.

1. Signal transduction by the JNK group of MAP kinases;Davis;Cell,2000

2. Targeting JNK for therapeutic benefit: from junk to gold?;Manning;Nat. Rev., Drug Discov.,2003

3. The true face of JNK activation in apoptosis;Lin;Aging Cell,2002

4. The JNK signal transduction pathway;Weston;Curr. Opin. Cell Biol.,2007

5. The JNK/c-Jun cascade and Alzheimer's disease;Okazawa;Am. J. Alzheimer's Dis. Other Demen.,2002

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation;Bioorganic & Medicinal Chemistry Letters;2024-04

2. The Role of the Dysregulated JNK Signaling Pathway in the Pathogenesis of Human Diseases and Its Potential Therapeutic Strategies: A Comprehensive Review;Biomolecules;2024-02-19

3. Development and Assessment of 1,5–Diarylpyrazole/Oxime Hybrids Targeting EGFR and JNK–2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation;Molecules;2023-09-08

4. A conserved arginine within the αC-helix of Erk1/2 is a latch of autoactivation and of oncogenic capabilities;Journal of Biological Chemistry;2023-09

5. Synthesis, molecular docking and evaluation of 1,5-diarylpyrazole/oxime hybrids targeting EGFR and JNK-2 as antiproliferative agents;2023-04-11